Policy & Regulation
Lonza Group agrees to make experimental COVID-19 antibody combination for AstraZeneca
30 October 2020 -

Swiss biotechnology company Lonza Group AG (Lonxa) (SWX: LONN) has agreed with British pharmaceutical company AstraZeneca Plc (STO: AZN) (LON: AZN) to make AZD7442, an experimental combination of two antibodies that may be used to prevent and treat COVID-19, Reuters news agency reported on Friday.

According to Lonxa, AZD7442 is in Phase I clinical studies and AstraZeneca plans to advance the combination into Phase III trials in the coming weeks.

Lonza will manufacture drug substance for AZD7442 at its facilities in the US.

These operations are expected to commence in the first half of 2021.

Login
Username:

Password:


Related Headlines

The Marshfield Clinic Research Institute joins TriNetX network

LISCure Biosciences and Mayo Clinic sign know-how license and development collaboration agreement and stock purchase agreement

ImmunoMet Therapeutics elects Dr Revati Shreeniwas as CMO

Mirum licenses its maralixibat to GC Pharma for the treatment of rare liver diseases in South Korea

CHMP grants positive opinion in the European Union for Otsuka's child-friendly 25 mg dispersible tablet formulation of Deltyba for the paediatric population weighing at least 10 kg with pulmonary multi-drug resistant tuberculosis

Brukinsa Approved in Canada for the Treatment of Patients with Mantle Cell Lymphoma

Adagio Therapeutics Partners with Biocon Biologics to Bring COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets

SpeeDx Launches Solution for SARS-CoV-2 Variant Analysis

NeoImmuneTech Receives US FDA IND Clearance for Phase 1 Study of NT-I7 for the Treatment of Kaposi Sarcoma in Patients with or Without HIV Infection

Synaffix Inks Deal with ProfoundBio Worth up to USD 246m Providing Access to Multiple Novel Linker-Payload Technologies

Slingshot Biosciences Closes USD 23m in Series A Financing

FDA Approves Keytruda Plus Lenvima Combination for Patients with Certain Types of Advanced Endometrial Carcinoma

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization for the Use of the Moderna COVID-19 Vaccine in Adolescents (12-17 Years of Age) in the European Union

Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections

Anivive's GC376 Reduces COVID-19 Replication, Shows Potential as New Post-Infection Treatment